Back to top
more

Sarepta Therapeutics (SRPT)

(Real Time Quote from BATS)

$15.93 USD

15.93
4,390,856

-0.82 (-4.90%)

Updated Aug 6, 2025 12:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CVS Health (CVS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

CVS Health's (CVS) fourth-quarter 2023 results are likely to reflect the strength of the Pharmacy & Consumer Wellness and Health Services segments.

Zacks Equity Research

TransCode (RNAZ) Down 50% on Issue of New Common Stock

by Zacks Equity Research

TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.

Zacks Equity Research

ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why

by Zacks Equity Research

ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.

Zacks Equity Research

Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug

by Zacks Equity Research

Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.

Zacks Equity Research

Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia

by Zacks Equity Research

This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.

Zacks Equity Research

Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up

by Zacks Equity Research

Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

Zacks Equity Research

Roche's (RHHBY) Tecentriq Subcutaneous Gets Approval in the EU

by Zacks Equity Research

Roche's (RHHBY) subcutaneous formulation of immuno-oncology drug Tecentriq receives EC's approval for all approved indications.

Zacks Equity Research

Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why

by Zacks Equity Research

Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.

Zacks Equity Research

Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why

by Zacks Equity Research

Iovance's (IOVA) surges on the anticipated FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Zacks Equity Research

Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why

by Zacks Equity Research

After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.

Zacks Equity Research

Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why

by Zacks Equity Research

The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.

Zacks Equity Research

Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine

by Zacks Equity Research

Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.

Zacks Equity Research

Aclaris (ACRS) Down 21% on Mixed Results From Eczema Study

by Zacks Equity Research

Though data from a mid-stage study shows that treatment with Aclaris' (ACRS) JAK inhibitor met its primary endpoint, it also displays a greater-than-expected placebo effect.

Zacks Equity Research

C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn

by Zacks Equity Research

The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.

Zacks Equity Research

Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results

by Zacks Equity Research

Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

The Zacks Analyst Blog Highlights DaVita, monday.com, GitLab, Light & Wonder and Sarepta Therapeutics

by Zacks Equity Research

DaVita, monday.com, GitLab, Light & Wonder and Sarepta Therapeutics are part of the Zacks top Analyst Blog.

Zacks Equity Research

Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday

by Zacks Equity Research

Sarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the company's DMD gene therapy. The company expects a potential approval in August.

Zacks Equity Research

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

by Zacks Equity Research

The FDA bestows a Fast Track Designation to SELLAS' (SLS) pipeline candidate, SLS009, for the treatment of relapsed/refractory acute myeloid leukemia. Stock gains.

Nalak Das headshot

5 Mid-Cap Stocks to Buy in a Volatile January

by Nalak Das

We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, MNDY, GTLB, LNW, SRPT.

Zacks Equity Research

GSK to Buy Private Biotech, Strengthen Respiratory Pipeline

by Zacks Equity Research

GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.

Zacks Equity Research

Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results

by Zacks Equity Research

Sarepta (SRPT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise.

Zacks Equity Research

Vericel Corporation (VCEL) Moves 7.0% Higher: Will This Strength Last?

by Zacks Equity Research

Vericel Corporation (VCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

by Zacks Equity Research

Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.